Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556828 · ClinicalTrials.gov registry record
Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 70
- Enrollment target
NCT01556828: Clinical Trial study, sponsored by Stanford University.
NCT01556828 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01556828 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 70 participants
- Enrollment target
Study Summary
The goal of this study is to identify genetic changes associated with the initiation, progression, and treatment response of response of cutaneous and hematologic disorders using recently developed high-throughput sequencing technologies. The improved understanding of the genetic changes associated with cutaneous and hematologic disorders may lead to improved diagnostic, prognostic and therapeutic options for these disorders.
Primary Outcome
Identify mutations, changes in DNA copy number, structural rearrangements, or altered coding and non-coding RNA expression
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-06 |
Why NCT01556828 stopped before completion
NCT01556828 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01556828 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01556828 about?
NCT01556828 is a clinical study titled "Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing". The goal of this study is to identify genetic changes associated with the initiation, progression, and treatment response of response of cutaneous and hematologic disorders using recently developed high-throughput sequencing technologies. The improved understanding of the genetic changes associated ...
What is the current status of trial NCT01556828?
This trial is currently terminated. The enrollment target is 70 participants. The study started on 2011-06. Estimated completion is 2014-06.
Who is sponsoring clinical trial NCT01556828?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia